These 10 Stocks Boast Double-Digit Gains Amid Boring Market

3. Scholar Rock Holding Corporation (NASDAQ:SRRK)

Scholar Rock jumped by 16.6 percent on Wednesday to close at $36.32 apiece as investor sentiment was bolstered by the positive results from the second phase of its weight loss drug trial.

In a statement, Scholar Rock Holding Corporation (NASDAQ:SRRK) said the trial, which aims to assess its drug candidate apitegromab’s combination with tirzepatide, was generally well tolerated, leading to higher quality weight loss as compared with taking tirzepatide alone.

According to Scholar Rock Holding Corporation (NASDAQ:SRRK), apitegromab therapy in combination with tirzepatide resulted in the preservation of 4.2 pounds of lean mass compared with tirzepatide alone.

“While this is an exciting development for our platform, we remain focused on preparing for the launch of apitegromab, and following its potential approval in SMA, we look forward to studying it in a range of neuromuscular diseases with high unmet need,” said Scholar Rock Holding Corporation (NASDAQ:SRRK) President and CEO Akshay Vaishnaw, adding that he was looking forward to exploring its potential in various rare, severe debilitating neuromuscular disorders.

“We remain on track to file an IND application for SRK-439 in the second half of this year to support the first in human study,” he said.